Pharmaceutical quality of inhalation and nasal products

  • Email
  • Help
Current effective version

Adopted guideline

Currently under revision

Reference numberCHMP/QWP/49313/2005
Published21/06/2006
Effective from01/10/2006
KeywordsInhalation, nasal, pharmaceutical quality, lung, pressurised metered dose inhalers, dry powder inhalers, products for nebulisation, non-pressurised metered dose inhalers, nasal sprays, nasal powders, nasal liquids
DescriptionThis document outlines expected quality aspects of human medicinal products intended for delivery of the active substance into the lungs, or to the nasal mucosa, with the purpose of evoking a local or systemic effect. These include pressurised metered dose inhalers, dry powder inhalers, products for nebulisation, and nonpressurised, metered dose inhalers, as well as pressurised metered dose nasal sprays, nasal powders, and nasal liquids.


Document history

Revision 1

In progress

Concept paper

Published: 22/03/2017

 

Deadline for comments: 22/06/2017

First version

Current version

Adopted guideline

In operation: 01/10/2006-present


Related content


How helpful is this page?

Average rating:

 Based on 2 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
2 ratings
    

Tell us more